Maxim analyst Allen Klee downgraded Marpai to Hold from Buy. The company’s Q3 results exceeded estimates, but the risk of dilution from its upcoming capital needs and the recent management changes balances its attractive technology and market opportunity, the analyst tells investors in a research note. The firm further cites the new management team having suspended guidance, with a call scheduled on 11/29 to discuss the strategic vision and initiatives in place.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRAI: